PEGylation of a vesicular stomatitis virus G pseudotyped lentivirus vector prevents inactivation in serum.
about
Essential role of microfibrillar-associated protein 4 in human cutaneous homeostasis and in its photoprotectionAltering the tropism of lentiviral vectors through pseudotyping.PEGylated Adenoviruses: From Mice to MonkeysViro-immune therapy: A new strategy for treatment of pancreatic cancerGene delivery strategies to promote spinal cord repairPros and Cons of Antigen-Presenting Cell Targeted Tumor VaccinesUnderstanding and altering cell tropism of vesicular stomatitis virusMolecular engineering of viral gene delivery vehiclesPeptide-based technologies to alter adenoviral vector tropism: ways and means for systemic treatment of cancerCocal-pseudotyped lentiviral vectors resist inactivation by human serum and efficiently transduce primate hematopoietic repopulating cells.Gene delivery to pancreatic exocrine cells in vivo and in vitro.Immobilization of pseudorabies virus in porcine tracheal respiratory mucus revealed by single particle tracking.Species differences in the pharmacology and toxicology of PEGylated helper-dependent adenovirusEffects of vector backbone and pseudotype on lentiviral vector-mediated gene transfer: studies in infant ADA-deficient mice and rhesus monkeys.Methods for gene transfer to the central nervous system.Polymers for gene delivery across length scales.Controlled inactivation of recombinant viruses with vitamin B2.Engineering a serum-resistant and thermostable vesicular stomatitis virus G glycoprotein for pseudotyping retroviral and lentiviral vectorsBATF inhibition prevent acute allograft rejection after cardiac transplantation.Viral vectors: from virology to transgene expressionPEGylation of bacteriophages increases blood circulation time and reduces T-helper type 1 immune responseCharacteristics of oncolytic vesicular stomatitis virus displaying tumor-targeting ligands.Lentiviral delivery of short hairpin RNAs"Marker of Self" CD47 on lentiviral vectors decreases macrophage-mediated clearance and increases delivery to SIRPA-expressing lung carcinoma tumorsTherapy for prion diseases: Insights from the use of RNA interference.Oncolytic virotherapyHydrogels for lentiviral gene delivery.Transfer and Expression of Small Interfering RNAs in Mammalian Cells Using Lentiviral VectorsFluorescence molecular painting of enveloped virusesFighting Cancer with Mathematics and Viruses.Genome editing for scalable production of alloantigen-free lentiviral vectors for in vivo gene therapy.Incorporation of VSV-G produces fusogenic plasma membrane vesicles capable of efficient transfer of bioactive macromolecules and mitochondria.Evolving lessons on nanomaterial-coated viral vectors for local and systemic gene therapy.Vesiculovirus neutralization by natural IgM and complement.Biomaterial-Guided Gene Delivery for Musculoskeletal Tissue Repair.A lentiviral vector pseudotype suitable for vaccine development.PEGylation of vesicular stomatitis virus extends virus persistence in blood circulation of passively immunized mice.Gene transfer in human skin with different pseudotyped HIV-based vectors.Incorporation of Viral Glycoprotein VSV-G Improves the Delivery of DNA by Erythrocyte Ghost into Cells Refractory to Conventional Transfection.Donor miR-196a-2 polymorphism is associated with hepatocellular carcinoma recurrence after liver transplantation in a Han Chinese population.
P2860
Q24305688-4C526FDD-46F6-41AF-B558-A7EC6790C63AQ24538987-90E1EB4E-98B8-4DAB-AE2F-7CEE71F36091Q24635276-BB497905-EAC1-4E5E-8869-61F07151B64EQ26774641-3468EC9C-3223-47ED-995A-7F36A5D4F0F0Q26825131-05104D9C-600B-4EE0-AC57-2415E51E73D5Q27013679-D6BFE078-793F-4268-854B-D92EC2BA58F9Q27687067-01E7182E-2E4F-49DF-A6F4-1FC032ED9573Q33353795-192C2531-A87F-4661-B4BC-089C6BC551B0Q33584756-A78D0CB0-DCD1-412C-8BDB-8AA476EEBBC0Q33822226-E3E677C4-AAAC-47F3-906F-1098B6F240D4Q34454159-A33C9A38-E4F1-4081-8D94-9B9834D8E467Q34510728-EE97B392-695C-48B1-8E6F-F8A6B9C2F467Q34975214-628DFC44-F6CE-4787-9AB1-105E76BEA777Q35596574-0C10AC1C-AC3D-419C-B34A-A4B5F3B85EE3Q35902332-7F42A4F9-561F-4203-AD47-DED1A4C4E79DQ36494142-B0C351AC-67D6-4163-9050-1BE3A3AF59CEQ36593399-0B7C12B2-852F-4E39-B888-81E12ED44762Q37075772-E0F30A8B-C96B-46CC-93EF-FBF9872FF469Q37228044-B74200C1-AE95-4134-9308-4329480FA99DQ37262766-A4F4CA93-9488-4D4B-B476-3E4CE9DC5F4BQ37274884-61DF3BBD-FAE6-4BA2-9573-90C5337C9667Q37336836-C1CD2FAF-4965-49FF-A9CF-89570648F2E1Q37430557-8BD8E3B2-BE8E-47F7-8D65-387BFEC47AFCQ37490583-7359A77F-A9C5-47A8-9F3A-FE41EBE3E278Q37549830-4F1ACC2E-9D52-4D3C-918A-2EA70C0F288EQ38025263-A02E41CC-7C6D-4EE3-80CF-FD754CBAF488Q38076509-F04B536B-D798-49E2-A065-EEF750092DACQ38118762-A1EA0C85-2DFD-485D-BFE6-B6BF0AE713C6Q38429618-31ACBBA7-2A5F-454E-B94A-8865A67E1CE6Q38612646-486DEF93-40B7-4113-826A-7651202CF231Q38694306-1F90F1A3-C233-4F1A-BD39-A66D37BC7566Q38771915-785D9A40-5B20-4F29-92B5-FD42652991C9Q38848060-E2B5BE19-3759-4E49-8849-59BAF7061BA7Q39013686-4EDB3ADE-C5BC-4B41-83C9-848A357A836EQ39122705-CD2BA33B-98EF-4069-9799-DD31A46E74EBQ39577673-7338C457-E959-485A-AB2A-DF7EC33B8ABFQ39788723-072E10C7-DC3E-48F5-AFD2-9CFC94FB6F97Q40458715-015F02E2-B195-4A4A-B594-7803DFA294DEQ40566919-686FB0D4-4748-46B3-8627-5C848EE82E99Q41002670-939B3576-67D8-4D73-9FAB-6AAAA28B538A
P2860
PEGylation of a vesicular stomatitis virus G pseudotyped lentivirus vector prevents inactivation in serum.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
PEGylation of a vesicular stom ...... revents inactivation in serum.
@en
type
label
PEGylation of a vesicular stom ...... revents inactivation in serum.
@en
prefLabel
PEGylation of a vesicular stom ...... revents inactivation in serum.
@en
P2093
P2860
P1433
P1476
PEGylation of a vesicular stom ...... revents inactivation in serum.
@en
P2093
Alberto Auricchio
Gregg Schumer
James M Wilson
Klause D Linse
Lane J Brunner
Maria A Croyle
Shellie M Callahan
P2860
P304
P356
10.1128/JVI.78.2.912-921.2004
P407
P577
2004-01-01T00:00:00Z